IL-17A was reported to modulate the severity of myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE), although the magnitude of this effect varies substantially between studies35–37. Here, IL17A is linked to experimental autoimmune encephalomyelitis.